Tele-rehab as effective as in-person speech therapy for stroke patients

Some patients may be hesitant to receive rehabilitation through telehealth services because they see the care as not as effective as in-person visits. According to a study published in Aphasiology, researchers found tele-rehab to be just as effective as in-persons visits.

"People with communication disorders, such as aphasia, are often provided with therapy only for the first few months after they have been diagnosed, despite evidence that therapy can benefit them for years," said Jed Meltzer, PhD, lead author and neurorehabilitation scientist at Baycrest's Rotman Research Institute. "Location can limit a patient's access to a speech-language pathologist, especially for individuals living in rural areas. Our study shows that telerehabilitation can remove this geographic barrier since participants saw similar recovery results."

The study enrolled 44 patients who had a communication disorder caused by a stroke. After an initial in-person assessment, patients in the intervention group received homework and customized treatment plans through a tablet. Weekly one-hour sessions were conducted over 10 weeks for patients in the control group. Results showed the tele-rehabilitation treatment was as effective as in-person therapy.

“Clinician-guided computer-based treatment is effective for producing widespread gains in language and communication skills in chronic stroke,” wrote Meltzer. “Linguistic gains are equivalent whether clinician services are provided via telerehabilitation equipment or in person. Communicative confidence may still benefit from in-person treatment, reinforcing the need for social engagement in addition to deficit-focused linguistic treatment.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.